Progress in Alzheimer's disease research in the last year

Journal of Neurology

Volumn 260, Issue 7, 2013, Pages 1936-1941

  Galimberti, Daniela ^a   Scarpini, Elio ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Alzheimer's disease; Biomarkers; Cerebrospinal fluid; Disease modifying drugs; Genetics; Imaging; Risk factors; Therapy

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BIOLOGICAL MARKER; CAD 106; NOOTROPIC AGENT; PLACEBO; THIOCTIC ACID; UBIQUINONE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIBODY RESPONSE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL FEATURE; CONTROLLED CLINICAL TRIAL (TOPIC); DELIRIUM; DISEASE ASSOCIATION; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL DISEASE; FRONTAL VARIANT FRONTOTEMPORAL DEMENTIA; GRAY MATTER; HUMAN; INJECTION SITE ERYTHEMA; MEDICAL RESEARCH; MENINGOENCEPHALITIS; MILD COGNITIVE IMPAIRMENT; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; RISK FACTOR; WHITE MATTER;

ALZHEIMER DISEASE; ANIMALS; COGNITION DISORDERS; HUMANS; RESEARCH;

EID: 84880302020     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-013-6921-3     Document Type: Article

References (26)

1. Griffin WS (2006) Inflammation and neurodegenerative diseases. Am J Clin Nutr 3(Suppl.):470S-474S
2. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6(8):734-746
3. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P (2010) Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 9(11):1118-1127
4. Davis DH, Muniz Terrera G, Keage H, Rahkonen T, Oinas M, Matthews FE, Cunningham C, Polvikoski T, Sulkava R, MacLullich AM, Brayne C (2012) Delirium is a strong factor for dementia in the oldest-old: a population-based cohort study. Brain 135(pt9):2809-2816
5. Prioni S, Fetoni V, Barocco F, Redaelli V, Falcone C, Soliveri P, Tagliavini F, Scaglioni A, Caffarra P, Concari L, Gardini S, Girotti F (2012) Stereotypic behaviours in degenerative dementias. J Neurol 259:2452-2459
6. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O (2012) Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69(1):98-106
7. Mattsson N, Rosén E, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek MM, Olde Rikkert M, Tsolaki M, Mulugeta E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Wallin A, Eriksdotter-Jönhagen M, Minthon L, Winblad B, Blennow K, Zetterberg H (2012) Age and diagnostic performance of Alzheimer disease in CSF biomarkers. Neurology 78(7):468-476
8. van Rossum IA, Vos SJ, Burns L, Knol DL, Scheltens P, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, L'italien G, van der Flier WM, Teunissen CE, Blennow K, Barkhof F, Rueckert D, Wolz R, Verhey F, Visser PJ (2012) Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology 79(17):1809-1816
9. Llano DA, Devanarayan V, Simon AJ, The Alzheimer's Disease Neuroimaging Initiative (ADNI) (2012) Evaluation of plasma proteomic data for Alzheimer disease state classification and the prediction of progression from mild cognitive impairment to Alzheimer disease. Alzheimer Dis Assoc Disord Sep 27. [Epub ahead of print]
10. Soares HD, Potter WZ, Pickering E, Kuhn M, Immermann FW, Shera DM, Ferm M, Dean RA, Simon AJ, Swenson F, Siuciak JA, Kaplow J, Thambisetty M, Zagouras P, Koroshetz WJ, Wan HI, Trojanowski JQ, Shaw LM, Biomarkers Consortium Alzheimer's Disease Plasma Proteomics Project (2012) Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch Neurol 69(10):1310-1317
11. Watabe-Rudolph M, Song Z, Lausser L, Schnack C, Begus-Nahrmann Y, Scheithauer MO, Rettinger G, Otto M, Tumani H, Thal DR, Attems J, Jellinger KA, Kestler HA, von Arnim CA, Rudolph KL (2012) Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease. Neurology 78(5):569-577
12. Ringman JM, Schulman H, Becker C, Jones T, Bai Y, Immermann F, Cole G, Sokolow S, Gylys K, Geschwind DH, Cummings JL, Wan HI (2012) Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations. Arch Neurol 69(1):96-104
13. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC, Dominantly Inherited Alzheimer Network (2012) Clinical and biomarkers changes in dominantly inherited Alzheimer's disease. New Engl J Med 367(9):795-804
14. Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, Fagan AM, Shah AR, Alvarez S, Arbelaez A, Giraldo M, Acosta-Baena N, Sperling RA, Dickerson B, Stern CE, Tirado V, Munoz C, Reiman RA, Huentelman MJ, Alexander GE, Langbaum JB, Kosik KS, Tariot PN, Lopera F (2012) Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol 11(12):1048-1056
15. Joshi A, Ringman JM, Lee AS, Juarez KO, Mendez MF (2012) Comparison of clinical characteristics between familial and non-familial early onset Alzheimer's disease. J Neurol 259:2182-2188
16. Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennow K, Lundmark J, Staufenbiel M, Orgogozo JM, Graf A (2012) Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 11(7):597-604
17. Galimberti D, Ghezzi L, Scarpini E (2013) Immunotherapy against amyloid pathology in Alzheimer's disease. J Neurol Sci 2013 Jan 5 [Epub ahead of print]
18. Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cottrell B, Montine TJ, Thomas RG, Aisen P, Alzheimer's Disease Cooperative Study (2012) Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol 69(7):836-841
19. Jeppsson F, Eketjäll S, Janson J, Karlström S, Gustavsson S, Olsson LL, Radesäter AC, Ploeger B, Cebers G, Kolmodin K, Swahn BM, von Berg S, Bueters T, Fälting J (2012) Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. J Biol Chem 287(49):41245-41257
20. Tartaglia MC, Zhang Y, Racine C, Laluz V, Neuhaus J, Chao L, Kramer J, Rosen H, Miller B, Weiner M (2012) Executive dysfunction in frontotemporal dementia is related to abnormalities in frontal matter white tracts. J Neurol 259:1071-1080
21. La Joie R, Perrotin A, Barré L, Hommet C, Mézenge F, Ibazizene M, Camus V, Abbas A, Landeau B, Guilloteau D, de La Sayette V, Eustache F, Desgranges B, Chételat G (2012) Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (Aβ) load in Alzheimer's disease dementia. J Neurosci 32(46):16265-16273
22. Lee ST, Chu K, Jung KH, Kim JH, Huh JY, Yoon H, Park DK, Lim JY, Kim JM, Jeon D, Ryu H, Lee SK, Kim M, Roh JK (2012) miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model. Ann Neurol 72(2):269-277
23. Tai HC, Serrano-Pozo A, Hashimoto T, Frosch MP, Spires-Jones TL, Hyman BT (2012) The synaptic accumulation of hyperphosphorylated oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol 181(4):1426-1435
24. Saman S, Kim W, Raya M, Visnick Y, Miro S, Saman S, Jackson B, McKee AC, Alvarez VE, Lee NC, Hall GF (2012) Exosomes-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem 287(6):3842-3849
25. Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, Hefferan MP, Van Gorp S, Nazor KL, Boscolo FS, Carson CT, Laurent LC, Marsala M, Gage FH, Remes AM, Koo EH, Goldstein LS (2012) Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 482(7384):216-220
26. Marques SC, Lemos R, Ferreiro E, Martins M, de Mendonça A, Santana I, Outeiro TF, Pereira CM (2012) Epigenetic regulation of BACE1 in Alzheimer's disease patients and in transgenic mice. Neuroscience 220:256-266